What Levation Pharma does

Levation Pharma is a clinical-stage pharmaceutical developer founded in 2017 and headquartered in Tel Aviv, Israel. The company's sole disclosed asset is LEV-102, a topical gel formulation based on oxymetazoline, an alpha-adrenergic agonist, designed to lift the upper eyelid and improve visual fields in patients with acquired blepharoptosis (drooping eyelid). The product applies a repurposed active pharmaceutical ingredient to a defined ophthalmic indication via a topical delivery route.

The company operates with an extremely lean team of 1-10 employees and has raised approximately $1.1 million across three rounds, all from Peregrine Ventures (2018, 2020, 2022). It is a privately held for-profit entity. The founder and CSO, Houman Hemmati, leads scientific direction. The company's website (levationpharma.com) currently displays only a verification/loading page, and no product timeline, clinical trial results, regulatory submissions, or commercial partnerships have been disclosed.

The business model is pre-revenue and dependent on continued equity financing from a single investor. As a clinical-stage drug developer targeting an ophthalmic indication with an established off-patent active ingredient, Levation Pharma's value proposition rests on the proprietary formulation and delivery approach for LEV-102, and on eventual regulatory approval and commercialization — none of which have been disclosed. Customer segmentation, pricing, and go-to-market strategy are not articulated in available data.

Name

Levation Pharma

Website

https://levationpharma.com

Company type

Private

Founded year

2017

Headcount range

1–10 employees

Short description

Levation Pharma is a clinical-stage pharmaceutical company developing LEV-102, a proprietary topical oxymetazoline gel intended to lift the upper eyelid and improve visual fields in patients with acquired blepharoptosis.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industries

Ophthalmic & Otic Generics (HLAIABAF), Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants) (HLAHAJAL)

Keywords

• Ophthalmic pharmaceuticals
• Topical drug delivery
• Eyelid ptosis treatment
• Specialty pharma development
• Prescription ophthalmic gels

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Levation Pharma develops LEV-102, a topical gel containing oxymetazoline intended to lift the upper eyelid and improve visual fields in patients with ptosis or related eyelid disorders. The product is positioned as a non-surgical, locally applied prescription therapeutic for ophthalmology use.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights2 records

Direct peers

• RVL Pharmaceuticals: Markets Upneeq (oxymetazoline HCl ophthalmic solution), the FDA-approved treatment for acquired blepharoptosis. Direct competitor using the same active ingredient for the same eyelid-lift indication, making it the closest analogue to LEV-102.
• Osmotica Pharmaceutical: Specialty ophthalmic and CNS pharmaceutical company with a portfolio that previously included Upneeq via its RVL subsidiary. Operates in the same specialty ophthalmic commercial channel that LEV-102 would need to access.
• Oyster Point Pharma: Develops therapeutics for ocular surface and eyelid/lacrimal gland conditions, including Tyrvaya (varenicline nasal spray) for dry eye. Comparable as a small specialty ophthalmic company developing novel-format drugs targeting eyelid/tear-film disorders.

Broad incumbents

• Aerie Pharmaceuticals: Specialty ophthalmic pharma focused on glaucoma, ocular hypertension, and dry eye (now part of Alcon). Comparable as a small-to-mid-cap ophthalmic drug developer that built commercial infrastructure for eye-care prescribers.
• Eagle Pharmaceuticals: Specialty pharma developing and commercializing differentiated injectable and ophthalmic products. Comparable as a specialty drug developer with experience in niche ophthalmic commercial channels.

Emerging players

• Aldeyra Therapeutics: Clinical-stage biotech developing novel small-molecule therapies for ocular inflammation and rare eye diseases. Comparable as a similarly sized, single-indication-focused ophthalmic drug developer navigating early-stage clinical and regulatory milestones.
• Kala Bio: Specialty ophthalmic company developing novel therapies for rare and serious eye diseases. Comparable as a small, focused ophthalmic drug developer with limited capital and a concentrated pipeline.
• Tarsus Pharmaceuticals: Specialty ophthalmic developer focused on eyelid/lash and ocular surface conditions (e.g., Xdemvy for Demodex blepharitis). Highly comparable target patient population (eyelid disorders) and prescriber channel (eye care specialists).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/levation-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Levation Pharma